Real-World Study of BCL-2 Inhibitor-Based Regimens in Chronic Lymphocytic Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This non-interventional, real-world cohort study aims to evaluate treatment patterns, clinical outcomes, and safety of BCL-2 inhibitor-based regimens in patients with CLL treated in routine clinical practice. Data collected from participating centers will be used to characterize patient demographics, disease characteristics, treatment exposure, effectiveness outcomes, and adverse events, thereby providing real-world evidence to support clinical decision-making and optimize patient management.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzona diagnoza białaczki limfocytowej lub podobnego nowotworu limfatycznego
- •Pacjent otrzymuje lub otrzymywał leczenie nowymi lekami z grupy inhibitorów BCL-2
- •Dostępne pełne informacje o stanie pacjenta przed leczeniem oraz co najmniej jeden wynik badań po rozpoczęciu leczenia
✗ Disqualifies
- •Brak ważnych informacji o stanie pacjenta przed leczeniem lub danych dotyczących otrzymanego leczenia, uniemożliwiający ocenę efektów i bezpieczeństwa
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Jiangsu Province Hospital
Nanjing, China
Trial contact
Huayuan ZHU
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.